EUVIMEDEUVIMED entdecken
Crossref

The mineralocorticoid receptor and its antagonist finerenone regulate hepatic lipid accumulation via the AMPK/SREBP1/FASN signaling

Shanpan Fu, Mingyan Zhang, Kai Wang, Shuai Huang, Yuemei Xi, Jiayu Chen, De Xie, Qian Zhang, Wanling Que, Xueling Ye, Shuyi Chen, Yayan Liu und 8 weitere

Molecular and Cellular Endocrinology · 2026-10 · 620 · 112845

DOI: 10.1016/j.mce.2026.112845 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2026-10. Verfasst von Shanpan Fu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China; Xiamen…. Hauptthemen laut MEDLINE: Sterol Regulatory Element Binding Protein 1, AMP-Activated Protein Kinases, Signal Transduction, Mineralocorticoid Receptor Antagonists. Die Arbeit nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD), closely linked to obesity and diabetes, remains poorly understood, with limited therapeutic options. The mineralocorticoid receptor (MR) has been implicated in metabolic dysregulation, yet its role in hepatic lipid metabolism remains incompletely defined. Finerenone, a non-steroidal MR antagonist, has demonstrated renal and cardiovascular benefits in diabetes , yet its effects on hepatic metabolism have not been fully explored. This study aimed to evaluate the hepatoprotective effects of finerenone in MASLD and elucidate the underlying mechanisms. MASLD models were established using db/db mice and free fatty acid-treated hepatocytes. Treatment with finerenone significantly reduced hepatic lipid accumulation in both in vitro and in vivo models. Mechanistically, MASLD was characterized by overactivation of hepatic MR signaling, evidenced by increased NR3C2 expression and upregulation of canonical MR target genes. Finerenone inhibits and antagonizes excessive MR activation, enhanced AMP-activated protein kinase (AMPK) phosphorylation, and downregulated sterol regulatory element-binding protein 1 (SREBP1) and fatty acid synthase (FASN), thereby inhibiting de novo lipogenesis. The lipid-lowering effects of finerenone were abrogated by AMPKα knockdown or inhibition, while NR3C2 knockdown mimicked the metabolic effects of finerenone without additive benefit, supporting an MR-dependent mechanism. Conversely, aldosterone reversed the lipid-lowering effects of finerenone through the AMPK/SREBP1/FASN pathway. In conclusion, finerenone alleviates hepatic lipid accumulation in MASLD, at least in part, by inhibiting MR signaling and modulating the AMPK/SREBP1/FASN pathway. These findings highlight a previously underrecognized role of MR in hepatic lipid metabolism and support finerenone as a potential therapeutic strategy for MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sterol Regulatory Element Binding Protein 1AMP-Activated Protein KinasesSignal TransductionMineralocorticoid Receptor AntagonistsLipid MetabolismReceptors, MineralocorticoidLiverNaphthyridinesFatty Acid Synthase, Type IAnimalsMaleMiceMice, Inbred C57BLLipogenesisHepatocytesFatty Liver

Stichwörter der Autor:innen

AMP-Activated protein kinaseFinerenoneMetabolic dysfunction–associated steatotic liver diseaseMineralocorticoid receptorMineralocorticoid receptor antagonist

Substanzen

Sterol Regulatory Element Binding Protein 1AMP-Activated Protein KinasesMineralocorticoid Receptor AntagonistsfinerenoneReceptors, MineralocorticoidNaphthyridinesSrebf1 protein, mouseFatty Acid Synthase, Type IFasn protein, mouse

Autor:innen und Institutionen

  • Department of Internal Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China; Xiamen Key Laboratory of Translational Medicine for Nucleic Acid Metabolism…
  • Department of Endocrinology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, Fujian, 361000, China.
  • Department of Health Evaluation Center, Osaka Gyoumeikan Hospital, Osaka, 554-0012, Japan.
  • Department of Diabetes, Endocrinology and Clinical Immunology Hyogo College of Medicine, Nishinomiya, Hyogo, 663-8501, Japan.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Fu, S., Zhang, M., Wang, K., Huang, S., Xi, Y., Chen, J., Xie, Zhang, Q., Que, W., Ye, X., Chen, S., Liu, Y., Wu, M., Xu, L., Ye, C., Yamamoto, T., Koyama, H., Li, C., Wu, Y., & Cheng, J. (2026). The mineralocorticoid receptor and its antagonist finerenone regulate hepatic lipid accumulation via the AMPK/SREBP1/FASN signaling. Molecular and Cellular Endocrinology, 620, 112845. https://doi.org/10.1016/j.mce.2026.112845

Vancouver

Fu S, Zhang M, Wang K, Huang S, Xi Y, Chen J, et al. The mineralocorticoid receptor and its antagonist finerenone regulate hepatic lipid accumulation via the AMPK/SREBP1/FASN signaling. Molecular and Cellular Endocrinology. 2026;620:112845. doi:10.1016/j.mce.2026.112845

BibTeX
@article{Fu2026,
  author = {Fu, Shanpan and Zhang, Mingyan and Wang, Kai and Huang, Shuai and Xi, Yuemei and Chen, Jiayu and Xie, De and Zhang, Qian and Que, Wanling and Ye, Xueling and Chen, Shuyi and Liu, Yayan and Wu, Mengni and Xu, Liushuang and Ye, Cuiying and Yamamoto, Tetsuya and Koyama, Hidenori and Li, Changgui and Wu, Yanhui and Cheng, Jidong},
  title = {The mineralocorticoid receptor and its antagonist finerenone regulate hepatic lipid accumulation via the AMPK/SREBP1/FASN signaling},
  journal = {Molecular and Cellular Endocrinology},
  year = {2026},
  volume = {620},
  pages = {112845},
  doi = {10.1016/j.mce.2026.112845}
}
Kostenlos starten →